SUSAN BEITZELL: Open Payments
NPI 1134639347 · ATHENS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,994 in 193 payments from 24 companies in 2025. Trend: 2023 $2,479 · 2024 $3,352 · 2025 $3,994
Food & beverage: $3,994
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 50 | $956 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 31 | $544 |
| Madrigal Pharmaceuticals | 11 | $324 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $308 |
| GENZYME CORPORATION | 8 | $189 |
| Janssen Biotech, Inc. | 7 | $188 |
| PFIZER INC. | 10 | $169 |
| Mallinckrodt Hospital Products Inc. | 7 | $159 |
| Boston Scientific Corporation | 2 | $154 |
| Ardelyx, Inc. | 8 | $149 |
Products named: XIFAXAN, DUPIXENT, REZDIFFRA, ENTYVIO, SKYRIZI, RINVOQ, TREMFYA, LINZESS.
Industry payments across GA — which companies pay providers there.
